Telix Pharmaceuticals's ROE % for the quarter that ended in Dec. 2025 was -2.31%. Telix Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2025 was 6.11.
Telix Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -0.38%.
Telix Pharmaceuticals ROE % Adjusted to Book Value Related Terms
Telix Pharmaceuticals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telix Pharmaceuticals ROE % Adjusted to Book Value Chart
TLX vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Telix Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -0.38% mean?
Telix Pharmaceuticals (TLX) has a ROE % Adjusted to Book Value of -0.38% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Telix Pharmaceuticals and its competitors.
Is Telix Pharmaceuticals' ROE % Adjusted to Book Value too high?
Telix Pharmaceuticals' current ROE % Adjusted to Book Value is -0.38%. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' ROE % Adjusted to Book Value compare to VRTX and REGN?
Telix Pharmaceuticals' ROE % Adjusted to Book Value of -0.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current ROE % Adjusted to Book Value is -0.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $27.71, compared to a current price of $10.90 — trading 60.7% below its estimated fair value. The current ROE % Adjusted to Book Value is -0.38%. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current ROE % Adjusted to Book Value is -0.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of $10.90 is trading 60.7% below its estimated GF Value™ of $27.71.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TLX:
ROE % Adjusted to Book Value: -0.38%
GF Value™: $27.71 vs. price of $10.90 (60.7% below fair value)
No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score
Get the complete analysis for TLX
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLX has been successfully added to your 
